Immunomedics, Inc., (NASDAQ: IMMU) today announced that sacituzumab govitecan, its lead investigational ADC, induced promising objective responses as a single ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast CancerMay 16, 2018 5:01 PM